ReviewCurrent allergy and asthma reports2015
Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- AI-based prediction of aspirin-exacerbated respiratory disease using nasal epithelial mRNA expression profiles.The journal of allergy and clinical immunology. Global · 2026Article
- Sweet taste receptor agonists attenuate macrophage IL-1β expression and eosinophilic inflammation linked to autophagy deficiency in myeloid cells.Clinical and translational medicine · 2022Article
- Associations between comorbidities and annual incidence plus frequency of asthma exacerbation hospitalisation during the past year: data from CARN study.BMC pulmonary medicine · 2022Article
- Ginsenoside F1 Attenuates Eosinophilic Inflammation in Chronic Rhinosinusitis by Promoting NK Cell Function.Journal of ginseng research · 2021Article
- The Role of Autophagy in Eosinophilic Airway Inflammation.Immune network · 2019Review
- Chinese expert consensus on diagnosis and management of severe asthma.Journal of thoracic disease · 2018Review
- Economics of Chronic Rhinosinusitis.Current allergy and asthma reports · 2017Review
- Contemporary Use of Corticosteroids in Rhinology.Current allergy and asthma reports · 2017Review
- Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.International journal of immunopathology and pharmacologyObservational
- Interferon-α action in cytokine profile in eosinophilic nasal polyp cultures.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the upper airways of which two major phenotypes exist, CRS without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP). Some patients with CRS have suboptimal response to current guideline treatments. These patients remain severe and uncontrolled by treatment and have a poor quality of life. It is highly important to identify both clinical and biological markers, so-called biomarkers, in this subset of patients. The presence of nasal polyps and comorbidity with asthma and with aspirin-exacerbated respiratory disease (AERD) are the most common clinical traits that have been associated to difficult-to-treat severe CRS. In addition to clinical traits, numerous biological markers, with known etiopathogenic roles in CRS, have been associated to difficult-to-treat or recalcitrant CRS. This review summarizes the existing knowledge of the clinical and biological markers associated to difficult-to-treat or uncontrolled severe CRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.